BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 35255263)

  • 1. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
    Tan DJH; Ng CH; Lin SY; Pan XH; Tay P; Lim WH; Teng M; Syn N; Lim G; Yong JN; Quek J; Xiao J; Dan YY; Siddiqui MS; Sanyal AJ; Muthiah MD; Loomba R; Huang DQ
    Lancet Oncol; 2022 Apr; 23(4):521-530. PubMed ID: 35255263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
    Li J; Zou B; Yeo YH; Feng Y; Xie X; Lee DH; Fujii H; Wu Y; Kam LY; Ji F; Li X; Chien N; Wei M; Ogawa E; Zhao C; Wu X; Stave CD; Henry L; Barnett S; Takahashi H; Furusyo N; Eguchi Y; Hsu YC; Lee TY; Ren W; Qin C; Jun DW; Toyoda H; Wong VW; Cheung R; Zhu Q; Nguyen MH
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):389-398. PubMed ID: 30902670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
    Ioannou GN; Green P; Kerr KF; Berry K
    J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
    Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
    Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Degasperi E; Colombo M
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
    Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
    QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease.
    Thomas JA; Kendall BJ; El-Serag HB; Thrift AP; Macdonald GA
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):159-169. PubMed ID: 38215780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis.
    Su JY; Deng ZJ; Teng YX; Koh YX; Zhang WG; Zheng MH; Xie S; Huo RR; Chen CJ; Ma L; Zhong JH
    BJS Open; 2023 Jan; 7(1):. PubMed ID: 36802244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
    Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
    Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.
    Benhammou JN; Aby ES; Shirvanian G; Manansala K; Hussain SK; Tong MJ
    Sci Rep; 2020 Jun; 10(1):9902. PubMed ID: 32555268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
    Seif El Dahan K; Daher D; Singal AG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
    Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
    Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
    Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
    Huang DQ; Noureddin N; Ajmera V; Amangurbanova M; Bettencourt R; Truong E; Gidener T; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Yoneda M; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Allen AM; Noureddin M; Loomba R
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):829-836. PubMed ID: 37419133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
    Navarroza AMC; Wong SN
    Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.